Impact of frailty on mortality after transcatheter aortic valve implantation - 18/04/17
, Artur Dziewierz, MD, PhD, Maciej Bagienski, MD, Lukasz Rzeszutko, MD, PhD, Danuta Sorysz, MD, PhD, Jaroslaw Trebacz, MD, PhD, Robert Sobczynski, MD, PhD, Marek Tomala, MD, PhD, Maciej Stapor, MD, PhD, Dariusz Dudek, MD, PhDAbstract |
Background |
We sought to investigate the relation between frailty indices and 12-month mortality after transcatheter aortic valve implantation (TAVI).
Methods |
We included 101 consecutive patients with severe aortic stenosis who have undergone TAVI. Frailty indices according to Valve Academic Research Consortium-2 recommendations (5-m walk test [5MWT] and hand grip strength) as well as other available scales of frailty (Katz index, Elderly Mobility Scale [EMS], Canadian Study of Health and Aging [CSHA] scale, Identification of Seniors at Risk [ISAR] scale) were assessed at baseline. The primary endpoint was 12-month all-cause mortality.
Results |
Twelve-month all-cause mortality was 17.8%. According to 5MWT, 17.8% were frail; hand grip test: 6.9%; Katz index: 17.8%; EMS: 7.9%; CSHA scale: 16.9%; and ISAR scale: 52.5%. Associations between frailty indices and 12-month all-cause mortality after TAVI were significant in Cox regression analysis (frail vs not frail, presented as hazard ratio[95%CI] adjusted for logistic EuroSCORE): for 5MWT, 72.38 (15.95-328.44); for EMS, 23.39 (6.89-79.34); for CSHA scale, 53.97 (14.67-198.53); for Katz index, 21.69 (6.89-68.25); for hand grip strength, 51.54 (12.98-204.74); and for ISAR scale, 15.94 (2.10-120.74). Similarly, such relationship was confirmed when 5MWT, EMS, and CSHA were used as continuous variables (hazard ratio [95%CI] adjusted for logistic EuroSCORE: for 5MWT per 1-second increase, 2.55 [1.94-3.37]; for EMS per 1-point decrease, 2.90 (1.99-4.21); and for CSHA per 1-point increase, 3.13 [2.17-4.53]).
Conclusions |
Our study confirmed a strong predictive ability of most of the proposed frailty indices for 12-month mortality after TAVI. For patients scheduled for TAVI, the use of frailty indices, which are easy and quick to assess on clinical basis but with strong performance, for example, 5MWT, EMS, or hand grip test, may be advocated.
Le texte complet de cet article est disponible en PDF.Plan
| Conflict of interest: None. |
Vol 185
P. 52-58 - mars 2017 Retour au numéro
Article précédent
- Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial
- Victoria M. Robinson, David B. Bharucha, Kenneth W. Mahaffey, Paul Dorian, Peter R. Kowey, SHIELD-2 Investigators
- Cardioversion and subsequent quality of life and natural history of atrial fibrillation
- Sean D. Pokorney, Sunghee Kim, Laine Thomas, Gregg C. Fonarow, Peter R. Kowey, Bernard J. Gersh, Kenneth W. Mahaffey, Eric D. Peterson, Jonathan P. Piccini, for the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?